Summary & Overview
HCPCS Q0518: Pharmacy Supply for HIV Pre‑Exposure Prophylaxis, 90-Day
HCPCS Level II code Q0518 identifies a pharmacy supplying fee for an FDA‑approved oral HIV pre‑exposure prophylaxis (PrEP) prescription covering a 90‑day supply. The code is significant nationally as PrEP access and adherence remain central to HIV prevention strategies; a distinct pharmacy supply code supports clear billing for multi‑month dispensing and helps track programmatic efforts to expand preventive medication access.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and practical billing implications, benchmarks where available, and policy and coverage considerations relevant to major national payers. The publication highlights how the code is used to bill for pharmacy supply of PrEP, typical settings for service delivery (retail and specialty pharmacies), and the role of a 90‑day dispensing interval in adherence and program design.
The analysis covers payer coverage patterns, payment benchmarks, and coding practice notes to help billing and compliance teams ensure consistent documentation and claims submission. Data not available in the input is explicitly noted where applicable; the summary focuses on nationally relevant information about code purpose, use, and payer scope rather than state‑specific rules.
Billing Code Overview
HCPCS Level II code Q0518 describes a pharmacy supplying fee for HIV pre-exposure prophylaxis FDA-approved prescription oral drug, per 90-days. This code represents a pharmacy service payment tied to furnishing an FDA-approved oral PrEP medication for a 90-day supply. The service type is pharmacy dispensing/supply of a prescription medication for HIV pre-exposure prophylaxis. The typical site of service is outpatient retail or specialty pharmacy settings where patients receive a 90-day prescription fill for PrEP.
Clinical & Coding Specifications
Clinical Context
A 28-year-old sexually active man who has sex with men presents to a community health clinic seeking HIV pre-exposure prophylaxis (PrEP). The clinician documents risk factors including multiple recent condomless sexual encounters and a partner of unknown HIV status. After a negative baseline HIV antigen/antibody test, normal renal function assessment (serum creatinine and estimated glomerular filtration rate), and screening for hepatitis B and sexually transmitted infections, a clinician writes an FDA‑approved oral PrEP prescription for a 90‑day supply of a medication such as emtricitabine/tenofovir. The clinic’s pharmacy processes and dispenses the 90‑day supply and bills the dispensing pharmacy fee using HCPCS Level II code Q0518 (Pharmacy supplying fee for HIV pre‑exposure prophylaxis FDA approved prescription oral drug, per 90‑days). Typical workflow steps include patient intake and risk assessment, baseline laboratory testing, prescription writing, pharmacy dispensing and counseling, and follow‑up monitoring visits at recommended intervals (e.g., 1 month after initiation and then every 3 months). Typical site of service is an outpatient clinic, community health center, or retail/ambulatory pharmacy that dispenses a 90‑day supply.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when dispensing requires substantially greater pharmacy services than usual (e.g., complex patient counseling or coordination). |